Infosys Q4 FY26 Earnings Analysis
Published 15 Aug 2026 | IT - Software | Market Cap: ₹4.8L Cr
Price
₹1,186.7
Market Cap
₹4.8L Cr
P/E Ratio
15.5
Earnings Summary
Volumes have remained flat over the past year, with expectations to stay flat or marginally positive over the next 12 months, contingent on macroeconomic environment improvements (Jayesh Sanghrajka, Page 45). - Revenue growth is guided at around 2.25% organic growth midpoint for FY27, slightly lower than FY26's 2.4%, with expected deflationary impacts from AI-driven productivity partially offset by growth in AI services and new areas (Pages 36, 39, 40). - AI-driven services are growing strongly and partially counterbalance deflation elsewhere (Pages 36, 39). - Large deal signings were strong at $15 bn with 55% net new, indicating robust pipeline and growth potential, supporting growth outlook (Page 40). - Acquisitions contribute incremental growth (e.g., Stratus adds approx. FY27 growth guidance: 1.5% to 3.5% in constant currency, with acquisitions like Stratus baked in (~25 bps); Optimum Healthcare and Versent JV not yet included due to pending approvals.
📊 Revenue & Sales Performance
- →Volumes have remained flat over the past year, with expectations to stay flat or marginally positive over the next 12 months, contingent on macroeconomic environment improvements (Jayesh Sanghrajka, Page 45).
- →Revenue growth is guided at around 2.25% organic growth midpoint for FY27, slightly lower than FY26's 2.4%, with expected deflationary impacts from AI-driven productivity partially offset by growth in AI services and new areas (Pages 36, 39, 40).
- →AI-driven services are growing strongly and partially counterbalance deflation elsewhere (Pages 36, 39).
- →Large deal signings were strong at $15 bn with 55% net new, indicating robust pipeline and growth potential, supporting growth outlook (Page 40).
- →Acquisitions contribute incremental growth (e.g., Stratus adds approx. 25 bps), with other acquisitions pending regulatory approvals not yet factored into guidance (Page 22).
- →Growth dependent on resolution of geopolitical issues and broader economic stability (Page 34).
📈 Profitability & Margins
- →FY27 growth guidance: 1.5% to 3.5% in constant currency, with acquisitions like Stratus baked in (~25 bps); Optimum Healthcare and Versent JV not yet included due to pending approvals.
- →Operating margin guidance for FY27: 20% to 22%, balancing wage hikes, productivity pass-throughs, AI investments, and offsets from Project Maximus.
- →FY26 margins stable at 21%, with investments in AI, sales, marketing, and talent absorbing currency gains and other benefits.
- →EPS growth: FY26 reported EPS grew 11% YoY; adjusted EPS grew 12.1% for full year, reflecting stable profitability despite headwinds.
- →Large deal pipeline and AI services momentum expected to support growth acceleration in FY27.
- →Acquisitions expected to add approximately 200-225 bps to growth once fully integrated, potentially leading to fastest growth in three years.
🏗️ Capital Expenditure Plans
- →Infosys has invested significantly in AI capabilities and talent, absorbing related costs within margins while maintaining margin stability.
- →There is continued investment in sales and marketing, including around AI talent acquisition and building AI competency.
- →The company has made strategic acquisitions in healthcare (Optimum Healthcare) and insurance (Versent JV), aimed at expanding into growing markets and enhancing platform expertise.
- →Acquisition-related costs are expected to impact margins by 60 to 70 basis points.
- →Infosys remains cautious and selective with acquisitions, focusing on strategic, cultural, and value fit to ensure effective integration.
- →There is an implied ongoing capital allocation towards AI partnerships with companies like OpenAI and Anthropic to strengthen their AI services.
- →The company is maintaining a similar level of third-party costs (e.g., subcontractors) in FY27 as FY26, with some reduction expected medium-term.
💰 Fundraising & Capital Structure
📋 Order Book & Pipeline
- →Infosys signed $15 billion in large deals in the last fiscal year, including 96 deals, with 55% being net new — indicating a strong and healthy orderbook.
- →This represents a 28% year-on-year increase in large deal signings.
- →The company indicated a robust pipeline and good deal momentum, though some slower client decision-making was noted in March, without a significant impact on large deal sign-ups.
- →The growth guidance for FY27 excludes the contribution from three recent acquisitions, which are expected to add 200 to 225 basis points of growth once factored in.
- →Regulatory approvals for acquisitions (e.g., Versent) are pending but progressing with responses to queries provided.
- →Overall, Infosys projects continued strong deal activity supported by AI services growth, though mindful of market competitiveness and macroeconomic factors.
Key Metrics
Frequently Asked Questions
What were Infosys Q4 FY26 results?
Volumes have remained flat over the past year, with expectations to stay flat or marginally positive over the next 12 months, contingent on macroeconomic environment improvements (Jayesh Sanghrajka, Page 45). - Revenue growth is guided at around 2.25% organic growth midpoint for FY27, slightly lower than FY26's 2.4%, with expected deflationary impacts from AI-driven productivity partially offset by growth in AI services and new areas (Pages 36, 39, 40). - AI-driven services are growing strongly and partially counterbalance deflation elsewhere (Pages 36, 39). - Large deal signings were strong at $15 bn with 55% net new, indicating robust pipeline and growth potential, supporting growth outlook (Page 40). - Acquisitions contribute incremental growth (e.g., Stratus adds approx. FY27 growth guidance: 1.5% to 3.5% in constant currency, with acquisitions like Stratus baked in (~25 bps); Optimum Healthcare and Versent JV not yet included due to pending approvals.
What is Infosys share price analysis?
Infosys currently shows a neutral. The stock trades at a P/E of 15.5 with a market cap of ₹481,570 Cr. Investors should review the full earnings analysis for detailed insights.
Is Infosys planning capital expenditure?
Infosys has invested significantly in AI capabilities and talent, absorbing related costs within margins while maintaining margin stability.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.